Cargando…
Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade
Diabetic kidney disease is the most frequent cause of end-stage renal disease. This implies failure of current therapeutic approaches based on renin-angiotensin system (RAS) blockade. Recent phase 3 clinical trials of paricalcitol in early diabetic kidney disease and bardoxolone methyl in advanced d...
Autores principales: | Perez-Gomez, Maria Vanessa, Sanchez-Niño, Maria Dolores, Sanz, Ana Belen, Martín-Cleary, Catalina, Ruiz-Ortega, Marta, Egido, Jesus, Navarro-González, Juan F., Ortiz, Alberto, Fernandez-Fernandez, Beatriz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485003/ https://www.ncbi.nlm.nih.gov/pubmed/26239562 http://dx.doi.org/10.3390/jcm4061325 |
Ejemplares similares
-
Juxtaglomerular apparatus hyperplasia under dual angiotensin blockade. A footprint of adequate RAS inhibition or a concern for renal fibrosis?
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2012) -
Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients
por: Hase, Michiyo, et al.
Publicado: (2013) -
Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy
por: Ravid, Mordchai
Publicado: (2009) -
Renin–angiotensin system blockade for the risk of cancer and death
por: Shen, Jian, et al.
Publicado: (2016) -
Management of proteinuria: blockade of the renin–angiotensin–aldosterone system
por: Athavale, Akshay, et al.
Publicado: (2020)